Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019.


Journal

BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488

Informations de publication

Date de publication:
27 07 2022
Historique:
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 30 7 2022
Statut: epublish

Résumé

To report the global, regional, and national burden of chronic obstructive pulmonary disease (COPD) and its attributable risk factors between 1990 and 2019, by age, sex, and sociodemographic index. Systematic analysis. Global Burden of Disease Study 2019. Data on the prevalence, deaths, and disability adjusted life years (DALYs) of COPD, and its attributable risk factors, were retrieved from the Global Burden of Disease 2019 project for 204 countries and territories, between 1990 and 2019. The counts and rates per 100 000 population, along with 95% uncertainty intervals, were presented for each estimate. In 2019, 212.3 million prevalent cases of COPD were reported globally, with COPD accounting for 3.3 million deaths and 74.4 million DALYs. The global age standardised point prevalence, death, and DALY rates for COPD were 2638.2 (95% uncertainty intervals 2492.2 to 2796.1), 42.5 (37.6 to 46.3), and 926.1 (848.8 to 997.7) per 100 000 population, which were 8.7%, 41.7%, and 39.8% lower than in 1990, respectively. In 2019, Denmark (4299.5), Myanmar (3963.7), and Belgium (3927.7) had the highest age standardised point prevalence of COPD. Egypt (62.0%), Georgia (54.9%), and Nicaragua (51.6%) showed the largest increases in age standardised point prevalence across the study period. In 2019, Nepal (182.5) and Japan (7.4) had the highest and lowest age standardised death rates per 100 000, respectively, and Nepal (3318.4) and Barbados (177.7) had the highest and lowest age standardised DALY rates per 100 000, respectively. In men, the global DALY rate of COPD increased up to age 85-89 years and then decreased with advancing age, whereas for women the rate increased up to the oldest age group (≥95 years). Regionally, an overall reversed V shaped association was found between sociodemographic index and the age standardised DALY rate of COPD. Factors contributing most to the DALYs rates for COPD were smoking (46.0%), pollution from ambient particulate matter (20.7%), and occupational exposure to particulate matter, gases, and fumes (15.6%). Despite the decreasing burden of COPD, this disease remains a major public health problem, especially in countries with a low sociodemographic index. Preventive programmes should focus on smoking cessation, improving air quality, and reducing occupational exposures to further reduce the burden of COPD.

Identifiants

pubmed: 35896191
doi: 10.1136/bmj-2021-069679
pmc: PMC9326843
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e069679

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from Shahid Beheshti University of Medical Sciences for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Références

Eur Respir J. 1997 Apr;10(4):822-7
pubmed: 9150319
Epidemiology. 2004 Mar;15(2):143-9
pubmed: 15127905
Front Public Health. 2021 Nov 23;9:740800
pubmed: 34888281
BMJ. 2005 Nov 5;331(7524):1050
pubmed: 16234255
BMC Pulm Med. 2019 Oct 17;19(1):181
pubmed: 31623601
Respir Med. 2003 Feb;97(2):115-22
pubmed: 12587960
Environ Int. 2012 Nov 15;49:141-51
pubmed: 23022875
Eur Respir J. 2006 Dec;28(6):1245-57
pubmed: 17138679
Respir Med. 2016 Dec;121:81-90
pubmed: 27888996
Sci Total Environ. 2021 Nov 20;796:148819
pubmed: 34265615
Respirology. 2016 Jan;21(1):14-23
pubmed: 26494423
Am J Respir Crit Care Med. 2018 Nov 1;198(9):1130-1139
pubmed: 29979608
Lancet Respir Med. 2015 Feb;3(2):159-170
pubmed: 25680912
Lancet. 2007 Sep 1;370(9589):765-73
pubmed: 17765526
Allergy Asthma Proc. 2015 Jan-Feb;36(1):4-10
pubmed: 25562549
Thorax. 2010 Jun;65(6):480-5
pubmed: 20522842
Lancet Respir Med. 2020 Jun;8(6):585-596
pubmed: 32526187
EClinicalMedicine. 2021 Mar;33:100789
pubmed: 33758801
Am J Respir Crit Care Med. 2018 Mar 1;197(5):611-620
pubmed: 29323928
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Int J Chron Obstruct Pulmon Dis. 2018 Apr 27;13:1353-1364
pubmed: 29731623
Atmos Chem Phys. 2018;18(20):15003-15016
pubmed: 30930942
Lancet Public Health. 2021 Jul;6(7):e472-e481
pubmed: 34051921
Respir Med. 2006 Jan;100(1):115-22
pubmed: 15893923
Am J Respir Crit Care Med. 2009 Oct 1;180(7):649-56
pubmed: 19556519
Ther Adv Respir Dis. 2011 Jun;5(3):217-24
pubmed: 21429981
J Glob Health. 2015 Dec;5(2):020415
pubmed: 26755942
Respir Res. 2006 Mar 29;7:52
pubmed: 16571126
Eur Respir J. 2006 Sep;28(3):523-32
pubmed: 16611654
Zhonghua Nei Ke Za Zhi. 2006 Dec;45(12):974-9
pubmed: 17326992
Eur Respir J. 2013 Dec;42(6):1472-83
pubmed: 23722617
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Lancet. 2020 Oct 17;396(10258):1160-1203
pubmed: 33069325
Am J Respir Crit Care Med. 2016 Apr 15;193(8):813-4
pubmed: 27082528
Int J Tuberc Lung Dis. 2008 Apr;12(4):458-64
pubmed: 18371275
Nepal J Epidemiol. 2016 Mar 31;6(1):525-7
pubmed: 27152232
Eur Respir J. 1994 May;7(5):954-60
pubmed: 8050554
N Engl J Med. 1999 Jun 17;340(24):1881-7
pubmed: 10369852
Eur Respir J. 2018 Jan 31;51(2):
pubmed: 29386343
Chronic Dis Transl Med. 2020 Jul 11;6(4):260-269
pubmed: 33336171
Respir Med. 2018 May;138:50-56
pubmed: 29724393
BMJ. 2020 Feb 19;368:m234
pubmed: 32075787
Arch Bronconeumol (Engl Ed). 2021 Jan;57(1):61-69
pubmed: 32950310
Lung India. 2019 Jan-Feb;36(1):14-19
pubmed: 30604700
PLoS Med. 2014 Mar 25;11(3):e1001621
pubmed: 24667834
Thorax. 2006 Jun;61(6):472-7
pubmed: 16517577
Clin Cornerstone. 2003;5(1):1-10
pubmed: 12739306
Lancet. 2006 Apr 15;367(9518):1216-9
pubmed: 16631861
J Environ Manage. 2005 Nov;77(3):252-66
pubmed: 16171931
Chest. 2009 Jan;135(1):173-180
pubmed: 19136405
Eur J Health Econ. 2020 Mar;21(2):181-194
pubmed: 31564007
Int J Chron Obstruct Pulmon Dis. 2013;8:231-8
pubmed: 23687444
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326

Auteurs

Saeid Safiri (S)

Tuberculosis and Lung Diseases Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Community Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Epidemiology and Biostatistics, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran.

Kristin Carson-Chahhoud (K)

Australian Centre for Precision Health, University of South Australia, South Australia, Australia.
School of Medicine, University of Adelaide, South Australia, Australia.

Maryam Noori (M)

Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Seyed Aria Nejadghaderi (SA)

Research Centre for Integrative Medicine in Aging, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Mark J M Sullman (MJM)

Department of Life and Health Sciences, University of Nicosia, Nicosia, Cyprus.
Department of Social Sciences, University of Nicosia, Nicosia, Cyprus.

Javad Ahmadian Heris (J)

Department of Allergy and Clinical Immunology, Paediatric Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.

Khalil Ansarin (K)

Rahat Breath and Sleep Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Ali Mansournia (MA)

Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Gary S Collins (GS)

Centre for Statistics in Medicine, NDORMS, Botnar Research Centre, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Ali-Asghar Kolahi (AA)

Social Determinants of Health Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran a.kolahi@sbmu.ac.ir.

Jay S Kaufman (JS)

Department of Epidemiology, Biostatistics, and Occupational Health, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH